AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The European Commission is suing AstraZeneca, saying the drugmaker delayed deliveries of its COVID-19 vaccines to the bloc. Stella Kyriakides, the European commissioner for health and food safety, tweeted Monday: "Our priority is to ensure #COVID19 vaccine deliveries take place to protect the health of [Europeans]."

The EU is suing AstraZeneca, saying the drugmaker delayed deliveries of its vaccines

Most of 11mln doses of the AstraZeneca PLC (LON:AZN) COVID-19 vaccine due to be shipped to the Netherlands will go unused, it has been revealed. Jaap van Deldon, head of the vaccination department of the country's public health institute, told AD newspaper the supplies won't be needed because the government has restricted its use due to concerns over rare blood clots.

Coronavirus: Netherlands won't use millions AstraZeneca vaccine doses, Valneva seeks 4,000 UK volunteers for jab trials

GlaxoSmithKline

GlaxoSmithKline Plc and AstraZeneca Plc publish quarterly results this week, with Britain's two biggest drugmakers both facing pressure from different quarters.

Vaccines, management in focus as GSK, AstraZeneca report

Sanofi

Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc's (NASDAQ: AZN) monoclonal antibody (mAb) nirsevimab has reached its primary endpoint in a Phase 3 trial, demonstrating protection against respiratory syncytial virus disease (RSV) in healthy infants. The data comes earlier than anticipated; regulatory submissions for all-infant indications are expected to begin in 2022.

Sanofi-AstraZeneca's Nirsevimab Hits Primary Endpoint Goal In Late-Stage RSV Disease In Infants

AstraZeneca PLC (LON:AZN) has posted a trio of good news in its oncology and respiratory pipeline, including two recommendations for approval. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended selumetinib for conditional marketing authorisation in the bloc for paediatric patients aged three years and above.

AstraZeneca posts trio of good news, including two EU approval recommendations for cancer drugs

BioNTech SE

Pfizer

Researchers found that 21 days after a single dose of either the Oxford-AstraZeneca or the Pfizer-BioNTech vaccine, new Covid-19 infections had fallen by 65%.

Single dose of Pfizer-BioNTech or Oxford-AstraZeneca vaccine reduces infection rate by 65%, study finds

Commission move causes concern about bringing case against key supplier of Covid vaccines

EU asks states to back legal action against AstraZeneca

The European Commission is reportedly working on legal proceedings against AstraZeneca Plc (NASDAQ: AZN) as the company cut COVID-19 vaccine deliveries to the European Union. The move comes as one step further as an E.U.

AstraZeneca Can Face Legal Action Over Vaccine Shortfalls To EU: Reuters

AstraZeneca's failure to deliver on agreed vaccine quotas seriously hampered the EU's vaccine rollout.

AstraZeneca Reportedly Faces Being Sued By The European Union Over A Covid Vaccine Delivery Shortfall

The European Commission told EU ambassadors on Wednesday that it was considering legal action against AstraZeneca for these delivery issues, four EU officials told CNBC.

EU prepares legal action against AstraZeneca over vaccine delivery issues

AstraZeneca PLC (LON:AZN) may face a legal challenge over COVID-19 vaccine deliveries as the Commission is preparing proceedings. "EU states have to decide if they (will) participate.

AstraZeneca faces legal challenge by EU over COVID-19 vaccine deliveries

Some investors might want to consider the big pharma stock despite its COVID-19 vaccine woes.

Is AstraZeneca a Bad-News Buy?

In the latest trading session, Astrazeneca (AZN) closed at $52.27, marking a +1.24% move from the previous day.

Astrazeneca (AZN) Gains As Market Dips: What You Should Know

Biogen

Johnson & Johnson

Moderna

Sarepta Therapeutics

Vertex Pharmaceuticals

Investors may want to pay close attention to news coming down the pike soon that could affect the share prices of several pharma companies. The next two months are likely to see a wave of important updates about key products.

Key Decisions Coming on Products From Vertex, AstraZeneca and Other Pharmas

BOSTON--(BUSINESS WIRE)--Reify Health has announced that AstraZeneca has selected StudyTeam to accelerate clinical development across its breast cancer therapy portfolio.

Reify Health Powers Patient Recruitment and Enrollment Across AstraZeneca's Extensive Breast Cancer Clinical Trial Pipeline

UXBRIDGE, England & CAMBRIDGE, England--(BUSINESS WIRE)--Daiichi Sankyo UK, Limited (hereafter, Daiichi Sankyo) and AstraZeneca UK today welcome the news that the National Institute for Health and Care Excellence (NICE) has recommended Enhertu® (trastuzumab deruxtecan) for use within the Cancer Drugs Fund (CDF) as an option for treating HER2 positive unresectable or metastatic breast cancer in adults who have received two or more prior anti-HER2 based therapies. In the UK, almost 54,000 cases o

ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER

Alexion Pharma

AstraZeneca (AZN) obtains U.S. Federal Trade Commission's permission for the Alexion acquisition. The deal is expected to close in the third quarter of 2021.

AstraZeneca (AZN) Gets FTC Clearance for Alexion Acquisition

An Emergency Use Authorization from the FDA should happen soon.

AstraZeneca's Vaccine Data Is Still Good Enough for U.S. Authorization

AstraZeneca is a hyper-growth blue chip that expects a return to dividend growth in 2022. With one of the most promising drug pipelines in the industry, it could expand far faster than what it's enjoyed historically.

AstraZeneca Is One Very Safe Hyper-Growth Blue Chip

AstraZeneca PLC (LON:AZN) said its planned acquisition of rare disease specialist Alexion Pharmaceuticals Inc has been cleared by the US Federal Trade Commission. The FTSE 100 pharma giant said the approval follows similar clearances in Canada, Brazil, Russia and other countries globally, with additional regulatory clearances still pending from territories including the UK, the EU and Japan.

AstraZeneca receives green light from US regulators for Alexion acquisition

The Norwegian government said it needs more time to decide whether to restart the use of AstraZeneca's COVID-19 vaccine, or permanently remove it from the country's immunization program.

Norway delays decision to ditch AstraZeneca vaccine, warning it could impact J&J rollout

The study has major implications given how regulators have reacted to blood-clot concerns.

Pfizer and Moderna Vaccines About as Likely to Trigger Blood Clots as AstraZeneca's, Study Finds

Denmark has stopped using AstraZeneca-Oxford University's COVID-19 vaccine, becoming the first country in the world to stop using the shot entirely, but did not rule out using it again at a "later date."  There is a "real risk of severe side effects associated with using the COVID-19 vaccine from AstraZeneca," the Danish Health Authority said in a statement Wednesday.

Denmark has banned AstraZeneca's COVID-19 vaccine after rare blood clot concerns

The risk of developing a blood clot after having COVID-19 is eight times higher than after being given the Oxford-AstraZeneca vaccine, according to a study by Oxford University.

Risk of blood clot after COVID is eight times higher than after AstraZeneca jab - study

A study by Oxford University found the number of people who receive blood clots after getting vaccinated with a coronavirus vaccine are about the same for those who get Pfizer and Moderna vaccines as they are for the AstraZeneca vaccine that was produced with the university's help. According to CBS News, based on a preprint study, 4 in 1 million people experience cerebral venous thrombosis after getting the Pfizer or Moderna vaccine, versus 5 in 1 million people for the AstraZeneca vaccine.

News for AstraZeneca Stock (AZN)